SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Cistron Biotechnology(CIST)$.30 -- Ignore unavailable to you. Want to Upgrade?

To: Steve Harmon who wrote (1417)9/14/1998 5:49:00 PM
From: Walter Morton  Read Replies (1) | Respond to of 2742
 
Please correct me before I get excited:

Pasteur Merieux Connaught would give CIST $33,000,000 over three years?

If that is true and it happens it seems to me that CIST should have about $3 million in net income on the average for the next three years:

($33 million / 3 year)- $6.6 million/yr for cost of goods sold) - $400,000 for operating expenses) + 400,000 for normal sales + 300,000 for normal licensing fees)- $1.7 million in taxes.

$3 Million of Net Income / 25.6 million shares outstanding = $.12

What is a typical price earnings ratio for a biotech stock -- 25?

Using 15 instead of 25 the stock would have a future value of $1.80
($.12 X 15).

Please stop me before I get excited about this CIST again.



To: Steve Harmon who wrote (1417)9/17/1998 10:18:00 PM
From: Walter Morton  Read Replies (1) | Respond to of 2742
 
Now Bloomberg is saying that Immunex will get FDA approval of its arthritus drug.

I wonder if CIST could have gotten the other $75 million from Immunex if it had continued the court case?


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News